Treatment of hepatitis C virus infection in patients of northern India
- 10 August 2004
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (9), 1058-1065
- https://doi.org/10.1111/j.1440-1746.2004.03405.x
Abstract
The purpose of the present study was to evaluate the therapeutic response of north Indian patients with chronic hepatitis C (CH-C) to two different treatment regimens of interferon and ribavirin.Consecutive patients with a diagnosis of CH-C attending the Liver Clinic at the All India Institute of Medical Sciences, New Delhi between April 1999 and April 2002 were included in the study. A competitive reverse transcription-polymerase chain reaction (RT-PCR) method developed in the authors' laboratory was used for quantification of hepatitis C virus (HCV)-RNA. Genotyping of HCV was also determined. The clinical, biochemical, virological and histological parameters were used to assess the therapeutic response among a clinical cohort of patients with chronic hepatitis C. They were treated with two different protocols (interferon [IFN]-alpha-2b, 3 million units daily and ribavirin 10.6 mg/kg daily in two divided doses for 6 months or IFN-alpha-2b, 3 million units thrice weekly and ribavirin 10.6 mg/kg daily for 6 months).Sixty-five patients with CH-C were included in the study. Blood transfusion (n = 28, 43%) and community-acquired (n = 23, 35%) HCV infections were the commonest. The mean HCV load was high (24.14 +/- 12.5 x 10(8) copies/mL). Genotype 2 and 3 were prevalent in 80% (41/51) of the patients. Forty-five patients received 3 million units of IFN thrice weekly and 20 received the same dose daily. All received the same dose of ribavirin. A sustained virological response (SVR) of 95% (19/20) was achieved among patients receiving daily IFN, whereas 64.4% (29/45) of those who received IFN thrice weekly had SVR. The virological relapse was significantly lower among patients who received daily IFN than in those treated with thrice weekly IFN (n = 1/20, 5% vs 10/39, 25.6%; P = 0.015). The proportion of patients receiving daily IFN among those achieving SVR (19/48, 40%) was significantly higher than the proportion of patients receiving similar therapy among patients without SVR (1/17, 6%; P = 0.02).Transfusion and community-acquired HCV infection were the major causes of CH-C. Genotype 2 and 3 HCV were most prevalent among these patients. Despite high viral load, these patients responded well to a combination of daily IFN-alpha-2b and ribavirin.Keywords
This publication has 30 references indexed in Scilit:
- Hepatitis C virus infection in the general population: A community-based study in West Bengal, IndiaHepatology, 2003
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Influence of Pre-treatment Factors on Outcome of Interferon-alpha Treatment of Patients with Chronic Hepatitis CScandinavian Journal of Infectious Diseases, 1999
- Clinical features of patients with chronic liver disease associated with hepatitis C virus genotype 1a/I in Okinawa, JapanJournal of Gastroenterology and Hepatology, 1997
- Diversity of genotypes of hepatitis C virus in southern IndiaJournal of General Virology, 1995
- Prevalence of hepatitis C virus sequence variants in south-east AsiaJournal of General Virology, 1995
- Diagnosis of hepatitis C virus‐associated chronic liver disease in India: Comparison of HCV antibody assay with a polymerase chain reaction for the 5′ noncoding regionJournal of Medical Virology, 1994
- Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis CDigestive Diseases and Sciences, 1994
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B HepatitisScience, 1989